Acquired Resistance to Osimertinib in

Acrylamides Aniline Compounds / pharmacology Carcinoma, Non-Small-Cell Lung / drug therapy ErbB Receptors / genetics Humans Indoles Lung Neoplasms / drug therapy Mutation Protein Kinase Inhibitors / pharmacology Pyrimidines
EGFR-mutated NSCLC acquired resistance osimertinib

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Jun 2022
Historique:
received: 11 05 2022
revised: 20 06 2022
accepted: 21 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (

Identifiants

DOI: 10.3390/ijms23136936 PMID: 35805940 PMC: PMC9266773
pubmed: 35805940
pii: ijms23136936
doi: 10.3390/ijms23136936
pmc: PMC9266773
pii:
doi:

Substances chimiques

Acrylamides 0
Aniline Compounds 0
Indoles 0
Protein Kinase Inhibitors 0
Pyrimidines 0
osimertinib 3C06JJ0Z2O
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Onco Targets Ther. 2018 Dec 18;12:51-56
pubmed: 30588029
Clin Cancer Res. 2018 Dec 15;24(24):6195-6203
pubmed: 30228210
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
J Thorac Oncol. 2020 Jan;15(1):18-21
pubmed: 31864549
J Thorac Oncol. 2018 Jun;13(6):e89-e91
pubmed: 29596911
J Thorac Oncol. 2018 Jul;13(7):e114-e116
pubmed: 29935846
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Ann Oncol. 2017 Oct 01;28(10):2451-2457
pubmed: 28961841
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
pubmed: 18227510
Ann Pharmacother. 2022 Apr;56(4):503-504
pubmed: 34344199
BMC Cancer. 2019 Jul 17;19(1):702
pubmed: 31315676
Clin Cancer Res. 2020 May 1;26(9):2244-2256
pubmed: 31953310
Ann Transl Med. 2019 May;7(9):207
pubmed: 31205925
Front Oncol. 2022 Mar 03;12:811247
pubmed: 35311091
Cancer Discov. 2022 Jan;12(1):74-89
pubmed: 34548309
J Thorac Oncol. 2019 Oct;14(10):1784-1793
pubmed: 31228622
J Thorac Oncol. 2022 Feb;17(2):309-323
pubmed: 34626838
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
J Thorac Oncol. 2019 Nov;14(11):1995-2002
pubmed: 31377341
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
ESMO Open. 2018 Feb 23;3(2):e000313
pubmed: 29531840
In Vivo. 2021 Sep-Oct;35(5):2941-2945
pubmed: 34410991
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Cancer Discov. 2018 Dec;8(12):1529-1539
pubmed: 30257958
Pharmacol Rep. 2020 Aug;72(4):799-813
pubmed: 32666476
Lancet Respir Med. 2020 Nov;8(11):1132-1143
pubmed: 32479794
Cancer Lett. 2017 Jan 28;385:51-54
pubmed: 27840244
J Clin Oncol. 2019 Feb 1;37(4):278-285
pubmed: 30550363
JTO Clin Res Rep. 2022 Feb 26;3(4):100303
pubmed: 35369607
Nat Commun. 2018 Nov 7;9(1):4655
pubmed: 30405134
J Thorac Oncol. 2020 Aug;15(8):1369-1375
pubmed: 32353596
Pharmacol Res. 2021 May;167:105583
pubmed: 33775864
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
Cancer Discov. 2019 Jul;9(7):926-943
pubmed: 31092401
J Thorac Oncol. 2016 Oct;11(10):e121-3
pubmed: 27257132
ESMO Open. 2021 Dec;6(6):100319
pubmed: 34837746
Cancer Treat Rev. 2017 Sep;59:117-122
pubmed: 28806542
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333
pubmed: 32565926
Nat Cancer. 2021 Apr;2(4):377-391
pubmed: 35122001
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
J Clin Oncol. 2005 Apr 10;23(11):2544-55
pubmed: 15753462
Clin Lung Cancer. 2021 May;22(3):201-209
pubmed: 33610453
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lung Cancer. 2020 Aug;146:70-77
pubmed: 32521387
ESMO Open. 2021 Oct;6(5):100271
pubmed: 34543864
Cancer Discov. 2020 May;10(5):674-687
pubmed: 32213539
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
Nat Commun. 2016 Jun 10;7:11815
pubmed: 27283993
J Clin Oncol. 2020 Jan 10;38(2):124-136
pubmed: 31411950
Lancet Oncol. 2019 Dec;20(12):1655-1669
pubmed: 31591063
Lung Cancer (Auckl). 2019 Mar 12;10:21-26
pubmed: 30881166
JCO Precis Oncol. 2018;2:
pubmed: 30957057
Thorac Cancer. 2020 Jan;11(1):140-149
pubmed: 31758670
Lancet Respir Med. 2018 Feb;6(2):107-116
pubmed: 29249325
JAMA Oncol. 2021 Mar 01;7(3):386-394
pubmed: 33410885
Mol Cancer Res. 2020 Apr;18(4):549-559
pubmed: 31941753
Intern Med. 2020 May 15;59(10):1291-1294
pubmed: 32101830
J Thorac Oncol. 2019 Nov;14(11):1982-1988
pubmed: 31254668
Ann Oncol. 2022 May;33(5):466-487
pubmed: 35176458
J Thorac Oncol. 2018 Sep;13(9):e169-e172
pubmed: 30166014
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
J Thorac Oncol. 2017 Mar;12(3):567-572
pubmed: 27923714
Thorac Cancer. 2020 Sep;11(9):2389-2397
pubmed: 32677256
J Thorac Oncol. 2017 Nov;12(11):1723-1727
pubmed: 28662863
J Thorac Oncol. 2018 Sep;13(9):1312-1323
pubmed: 29883838
J Thorac Oncol. 2017 Nov;12(11):1728-1732
pubmed: 28843359
Lung Cancer. 2018 Apr;118:105-110
pubmed: 29571987
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Arch Pathol Lab Med. 2018 Feb;142(2):163-167
pubmed: 29106293
Lancet Oncol. 2014 Oct;15(11):1236-44
pubmed: 25175099
Ann Oncol. 2020 Nov;31(11):1536-1544
pubmed: 32861806
Thorac Cancer. 2021 Jun;12(11):1708-1715
pubmed: 33943009
J Thorac Oncol. 2018 Nov;13(11):e232-e234
pubmed: 30368417
Clin Cancer Res. 2020 Jun 1;26(11):2654-2663
pubmed: 31911548
Cancer Res. 2015 Jun 15;75(12):2489-500
pubmed: 25870145
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
J Clin Oncol. 2020 Jun 18;:JCO1903123
pubmed: 32552277
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
J Thorac Oncol. 2022 May;17(5):718-723
pubmed: 35181499
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Cancers (Basel). 2020 Dec 22;13(1):
pubmed: 33374971
J Thorac Oncol. 2015 Dec;10(12):1713-9
pubmed: 26334752
Clin Lung Cancer. 2021 May;22(3):e390-e394
pubmed: 32693944
J Clin Oncol. 2020 Jan 10;38(2):115-123
pubmed: 31682542
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
Mol Cancer Res. 2019 Feb;17(2):499-507
pubmed: 30463991
Clin Cancer Res. 2009 May 15;15(10):3484-94
pubmed: 19447865
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Cancers (Basel). 2022 Apr 26;14(9):
pubmed: 35565285
Oncogene. 2019 Jan;38(5):656-670
pubmed: 30171258
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
J Clin Oncol. 2018 Nov 1;36(31):3101-3109
pubmed: 30156984

Auteurs

Elisa Bertoli (E)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.

Elisa De Carlo (E)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Alessandro Del Conte (A)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Brigida Stanzione (B)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
ORCID: 0000-0002-0475-7399

Alberto Revelant (A)

Dipartimento di Radioterapia, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
ORCID: 0000-0002-4505-9650

Kelly Fassetta (K)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Michele Spina (M)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Alessandra Bearz (A)

Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acrylates › Acrylamides › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indoles › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Acquired Resistance to Osimertinib in
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Acquired Resistance to Osimertinib in